Promising research suggests that blosozumab, the new monoclonal agent , could provide a crucial breakthrough in the approach of cardiovascular dysfunction . This clinical results show a encouraging impact on vital biomarkers involved in myocardial fibrosis and swelling , potentially resulting in im